Q2 2026 revenue fell 11% year-over-year due to lower average revenue per test and payer friction, prompting revised FY 2026 guidance. Cancer Care saw volume growth but revenue decline, while new product launches and efficiency initiatives are underway.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.